Indication
Metastatic Cancer
Aliases
Metastatic cancer
168 clinical trials
214 products
37 drugs
Clinical trial
Phase I/II, Multi Center, Open Label, First-in-human, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, and Anti-tumors Efficacy of the Glyco-humanized Polyclonal Antibody XON7 in Patients With Advanced or Metastatic Solid TumorsStatus: Recruiting, Estimated PCD: 2026-12-01
Clinical trial
A Phase I/IIa, Open-label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the DNA Polymerase Theta Inhibitor ART4215 Administered Orally as Monotherapy and in Combination to Patients With Advanced or Metastatic Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2025-08-01
Product
ART4215Product
XON7Product
TalazoparibProduct
NiraparibProduct
CF33-hNISProduct
PembrolizumabClinical trial
A Phase I, Dose Escalation Safety and Tolerability Study of VAXINIA (CF33-hNIS), Administered Intratumorally or Intravenously as a Monotherapy or in Combination With Pembrolizumab in Adult Patients With Metastatic or Advanced Solid Tumors (MAST).Status: Recruiting, Estimated PCD: 2024-12-01
Product
[177Lu]Lu-SN201Clinical trial
A Phase I/IIa, Dose Escalation and Dose Expansion, First-in-human, Open-label, Multicenter, Single-arm Study Evaluating the Safety, Tolerability, Dosimetry, and Early Efficacy of [177Lu]Lu-SN201 in Participants With Progressive or Treatment-refractory Locally Advanced Unresectable, Metastatic or Recurrent Solid TumorsStatus: Recruiting, Estimated PCD: 2027-12-01
Clinical trial
A Phase 1, First-in-Human Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab, in Patients With Advanced Solid MalignanciesStatus: Recruiting, Estimated PCD: 2025-06-01
Product
NTX-1088Clinical trial
A Phase 1/2 Trial of MRTX849 in Combination With TNO155 in Patients With Advanced Solid Tumors With KRAS G12C Mutation KRYSTAL 2Status: Active (not recruiting), Estimated PCD: 2024-03-01
Product
TNO155Product
CAN1012Clinical trial
A Phase 1, Dose Escalation, Open-Label Study of Intratumoral CAN1012 in Subjects With Unresectable or Metastatic Advanced Solid TumorsStatus: Recruiting, Estimated PCD: 2024-12-30
Clinical trial
A Phase 1/2 Trial of Adagrasib in Combination With Nab-Sirolimus in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer With a KRAS G12C MutationStatus: Recruiting, Estimated PCD: 2025-12-31
Product
nab-SirolimusProduct
MRTX849Product
AdagrasibClinical trial
A Phase I/IIa Study of Intra-tumoral BT-001 (TG6030) Administered Alone and in Combination With Pembrolizumab in Patients With Cutaneous or, Subcutaneous Lesions or Easily Injectable Lymph Nodes of Metastatic/Advanced Solid Tumors.Status: Recruiting, Estimated PCD: 2025-04-30
Product
BT-001Clinical trial
A Phase 1/2, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of INX-315 in Patients With Advanced CancerStatus: Recruiting, Estimated PCD: 2025-12-01
Product
INX-315Product
FOG-001Clinical trial
A Phase 1/2 Study of FOG-001 in Participants With Locally Advanced or Metastatic Solid TumorsStatus: Recruiting, Estimated PCD: 2027-04-01
Clinical trial
A Phase 1 Dose-Escalation and Expansion Study of Intratumorally Administered ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and LymphomasStatus: Recruiting, Estimated PCD: 2026-04-30
Product
AU-007Clinical trial
A Phase 1/2, First-in-Human, Open Label, Dose Escalation and Expansion Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic CancerStatus: Recruiting, Estimated PCD: 2024-10-31
Product
ONM-501Product
CemiplimabClinical trial
A Phase 1, Multicenter, Open-label, Dose- Escalation, Safety, Pharmacodynamic, Pharmacokinetic Study of Q702 With a Cohort Expansion at the RP2D in Patients With Advanced Solid TumorsStatus: Recruiting, Estimated PCD: 2024-12-31
Product
Q702Product
AldesleukinProduct
CJRB-101Clinical trial
Phase 1/2 Open Label, Safety and Preliminary Efficacy Study of a Live Biotherapeutic Product (CJRB-101) in Combination With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic CancerStatus: Recruiting, Estimated PCD: 2026-07-01
Product
MEM-288Product
NivolumabClinical trial
A Phase 1b/2a Study of Gemcitabine and Nab-paclitaxel in Combination With Avutometinib (VS-6766) and Defactinib in Patients With Previously Untreated Metastatic Adenocarcinoma of the PancreasStatus: Recruiting, Estimated PCD: 2025-05-31
Clinical trial
Phase I Study of MEM-288 Oncolytic Virus Alone and in Combination With Nivolumab in Solid Tumors Including Non-Small Cell Lung Cancer (NSCLC)Status: Recruiting, Estimated PCD: 2025-11-01
Clinical trial
A First-in-human (FIH), Multicenter, Open-Label, Phase Ia (Dose Escalation)/Phase Ib (Dose Expansion) Study of PTX-912 in Patients With Locally Advanced/Metastatic Solid TumorsStatus: Not yet recruiting, Estimated PCD: 2026-05-14
Product
PTX-912Clinical trial
A Single-Arm Phase-II Study of Niraparib in Locally Advanced or Metastatic Solid Tumor Patients With PALB2 MutationsStatus: Active (not recruiting), Estimated PCD: 2024-06-01
Clinical trial
A Phase 2 Multi-center Open-label Basket Trial of Nab-sirolimus for Adult and Adolescent Patients With Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 or TSC2 Genes.Status: Recruiting, Estimated PCD: 2024-12-31
Product
nab-sirolimusProduct
DS-9606aClinical trial
Phase 1b Dose-Finding Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042 in Patients With Advanced or Metastatic CancerStatus: Active (not recruiting), Estimated PCD: 2020-02-26
Clinical trial
A Phase 1a/b, Open-Label, Dose-Escalation and Expansion Study of IK-175, an Oral Aryl Hydrocarbon Receptor (AHR) Inhibitor, as a Single Agent and in Combination With Nivolumab, a PD-1 Checkpoint Inhibitor in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial CarcinomaStatus: Completed, Estimated PCD: 2023-07-18
Product
IK-175 + NivolumabProduct
TSR-042Product
Carboplatin-PaclitaxelProduct
BevacizumabProduct
TSR-022Product
IK-175Clinical trial
A Phase 1, First-in-Human Study of DS-9606a in Patients With Tumor Types Known to Express Claudin-6 (CLDN6)Status: Recruiting, Estimated PCD: 2026-02-19
Product
Carboplatin-PemetrexedProduct
Carboplatin-Nab-PaclitaxelClinical trial
A Phase I Clinical Study to Assess the Safety and Efficacy of CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Gynecologic CancerStatus: Recruiting, Estimated PCD: 2026-12-31
Product
CD70 CAR-T cellsProduct
ASP9801Clinical trial
A Phase 1, Open-label Study of ASP9801, an Oncolytic Virus, Administered by Intratumoral Injection as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced/Metastatic Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2024-04-30
Clinical trial
A Phase 1, Open-Label, First-in-Human Study to Evaluate the Safety and Anti-tumour Activity of FS222, a CD137/PD-L1 Bispecific Antibody, in Subjects With Advanced MalignanciesStatus: Recruiting, Estimated PCD: 2025-05-01
Clinical trial
A First-in-human (FIH) Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST) [Study ID: StrateGIST 1]Status: Recruiting, Estimated PCD: 2026-04-24
Product
IDRX-42Product
FS222Product
PC14586Product
pembrolizumabClinical trial
A Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients With Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)Status: Recruiting, Estimated PCD: 2026-03-17
Product
Avutometinib + DefactinibProduct
GEN2Clinical trial
A Phase 1 Dose Escalation Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of GEN2 in Refractory Patients With Primary Hepatocellular Carcinoma or Tumors Metastatic to the LiverStatus: Active (not recruiting), Estimated PCD: 2024-06-30
Product
MGC026Clinical trial
A Phase 1/1b First-in-Human, Open Label, Dose Escalation and Cohort Expansion Study of MGC026 in Participants With Advanced Solid TumorsStatus: Recruiting, Estimated PCD: 2028-05-01
Product
IK-175 and NivolumabProduct
CD70 CAR-TClinical trial
A Phase 1/1b Open-Label Study to Evaluate the Safety and Antitumor Activity of FS120, an OX40/CD137 Bispecific Antibody, Alone and in Combination With Pembrolizumab, in Subjects With Advanced MalignanciesStatus: Recruiting, Estimated PCD: 2026-03-01
Product
FS120Product
JK08Clinical trial
A Phase 1/2, Multicenter, Open Label, Dose Escalation & Dose Expansion Study of JK08, an IL-15 Antibody Fusion Protein Targeting CTLA-4, Monotherapy or in Combination in Patients With Unresectable Locally Advanced or Metastatic CancerStatus: Recruiting, Estimated PCD: 2025-10-17
Clinical trial
A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SNS-101 (Anti VISTA) as Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid TumorsStatus: Recruiting, Estimated PCD: 2027-06-01
Product
SNS-101Product
PD-L1 t-haNKClinical trial
Open-Label Phase 1 Study of PD-L1 t-haNK In Subjects With Locally Advanced Or Metastatic Solid CancersStatus: Active (not recruiting), Estimated PCD: 2024-06-01
Clinical trial
A Phase 1, Dose Escalation Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01)Status: Active (not recruiting), Estimated PCD: 2022-02-01
Product
RituximabProduct
EvorpaceptProduct
Ramucirumab + PaclitaxelProduct
5-FU + CisplatinProduct
CTX-471Product
KeytrudaClinical trial
A Phase 2 Trial of Cryosurgical Freezing and Multiplex Immunochemotherapy in Patients With Metastatic Solid CancerStatus: Active (not recruiting), Estimated PCD: 2024-12-01
Product
CytoxanProduct
GM-CSFClinical trial
A Phase 1, Open-Label, Multiple-Ascending Dose Study of the Safety and Tolerability of CTX-471 Administered Either as a Monotherapy or in Combination With Pembrolizumab in Patients With Inadequate Responses to PD-1/PD-L1 Checkpoint Inhibitors in Metastatic or Locally Advanced MalignanciesStatus: Recruiting, Estimated PCD: 2025-02-01
Clinical trial
A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of KY1044 as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced MalignanciesStatus: Active (not recruiting), Estimated PCD: 2024-08-05
Product
KY1044Product
Yervoy InjectableClinical trial
A Phase 1/2 Multicenter, Open-label, Dose-escalation, Safety, Pharmacodynamic, and Pharmacokinetic Study of Q901Administered Via Intravenous Infusion as Monotherapy and in Combination With Pembrolizumab in Adult Patients With Selected Advanced Solid Tumors With Cohort Expansions at the Recommended Phase 2 DoseStatus: Recruiting, Estimated PCD: 2025-12-30
Product
Q901Product
KY1044 and AtezolizumabProduct
LYT-200Clinical trial
A Phase 1/2 Open-label, Multi-center Study of the Safety, Pharmacokinetics, and Anti-tumor Activity of LYT-200 as a Single Agent and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid TumorsStatus: Recruiting, Estimated PCD: 2024-09-01
Product
TislelizumabProduct
Gemcitabine/nab-paclitaxelProduct
YervoyClinical trial
A Phase I/IIa, Open-label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients With Advanced or Metastatic Solid TumorsStatus: Recruiting, Estimated PCD: 2025-06-01
Product
ART0380Product
GemcitabineProduct
IrinotecanClinical trial
A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients With Advanced Solid Tumors With KRAS G12C Mutation KRYSTAL-1Status: Recruiting, Estimated PCD: 2025-07-01
Product
CetuximabProduct
AfatinibProduct
Avutometinib + AdagrasibClinical trial
Expanded Access Use of Adagrasib (MRTX849) for the Treatment of Patients With Advanced Solid Tumors With a KRAS G12C MutationStatus:
Clinical trial
A Phase 3 Randomized, Open-Label, Multicenter Clinical Study of CGT9486+Sunitinib vs. Sunitinib in Subjects With Locally Advanced, Unresectable, or Metastatic Gastrointestinal Stromal TumorsStatus: Recruiting, Estimated PCD: 2025-07-01
Product
CGT9486Product
SunitinibClinical trial
A Randomized Study of Two Dosing Regimens of Adagrasib in Patients With Previously Treated Non-Small Cell Lung Cancer With KRAS G12C MutationStatus: Recruiting, Estimated PCD: 2025-03-01
Product
INCAGN01876Clinical trial
A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic MalignanciesStatus: Completed, Estimated PCD: 2021-11-09
Product
IpilimumabClinical trial
A Phase 1/2 Study of Avutometinib (VS-6766) in Combination With Adagrasib in Patients With KRAS G12C Mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 204)Status: Recruiting, Estimated PCD: 2024-07-24
Product
VE800Product
VancomycinClinical trial
A Phase 1/2 Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BMS-863233 in Subjects With Advanced and/or Metastatic Solid TumorsStatus: Terminated, Estimated PCD: 2010-08-04
Clinical trial
A Dose Finding Study of CycloSam® (153-Sm-DOTMP) to Treat Solid Tumor(s) in the Bone or Metastatic to the Bone (Metastatic Prostate, Breast, and Lung, Osteosarcoma, Ewing's Sarcoma, and Other Solid Tumor(s) to the Bone All Eligible)Status: Recruiting, Estimated PCD: 2024-04-05
Product
Cdc7-inhibitorClinical trial
Phase 1 Study of VE800 and Nivolumab in Patients With Selected Types of Advanced or Metastatic CancerStatus: Completed, Estimated PCD: 2021-08-26
Product
TJ210001Clinical trial
A Phase 1 Study of TJ210001 Administered in Subjects With Relapsed or Refractory Advanced Solid TumorsStatus: Completed, Estimated PCD: 2022-11-21
Clinical trial
Phase 1, Open-Label, Safety Study of Escalating Doses of Ex Vivo Expanded, Autologous Natural Killer Cells in Patients With Pathologically Confirmed Cancer Refractory to Conventional TherapyStatus: Completed, Estimated PCD: 2023-02-17
Product
SNK01Product
AvelumabProduct
153-Sm-DOTMPProduct
OB-002Clinical trial
A Phase 1b, Open-label, Non-randomized Trial for the Assessment of Safety, Tolerability, and Pharmacokinetics of OB-002 as a Monotherapy in Patients With Refractory Metastatic Colorectal, Pancreatic, Gastric, Breast, or Urothelial CancerStatus: Not yet recruiting, Estimated PCD: 2025-04-01
Clinical trial
A Non-randomized Cohort Study With Matched Controls Investigating Pharmacokinetic Parameters and Safety of a Single Dose of Pixantrone With Metastatic Cancer and Moderate, Severe, or No Hepatic Impairment.Status: Withdrawn, Estimated PCD: 2017-08-01
Clinical trial
Phase I/IIa, First-in-human, Open-label, Dose Escalation Trial With Expansion Cohorts to Evaluate Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of BNT141 as a Monotherapy and in Combination With Other Anti-cancer Agents in Patients With CLDN18.2-positive Solid TumorsStatus: Terminated, Estimated PCD: 2023-07-24
Product
Nab-paclitaxelClinical trial
A Phase I Dose Escalation Study of the Safety, Pharmacokinetics and Pharmacodynamics of MRX-2843 in Adult Subjects With Relapsed/Refractory Advanced and/or Metastatic Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2023-12-01
Product
FS118Clinical trial
A Phase 1/2, Open-Label, Study to Evaluate the Safety and Anti-Tumor Activity of FS118, a LAG-3/PD-L1 Bispecific Antibody, as a Monotherapy and in Combination With Paclitaxel, in Patients With Advanced MalignanciesStatus: Active (not recruiting), Estimated PCD: 2024-06-01
Product
PaclitaxelProduct
INCB001158Product
PixantroneClinical trial
Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Arginase Inhibitor INCB001158 (Formerly Known as CB1158) as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid TumorsStatus: Completed, Estimated PCD: 2020-08-31
Product
BNT141Clinical trial
A Phase 1/2 Study of OR502 Alone and in Combination With Other Anti-cancer Agents in Subjects With Advanced MalignanciesStatus: Recruiting, Estimated PCD: 2026-08-01
Product
OR502Product
OzuriftamabClinical trial
A Phase 2 Open-Label Study of Ozuriftamab Vedotin (BA3021) in PD-1/L1 Failure Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckStatus: Recruiting, Estimated PCD: 2024-12-01
Product
PD-1 inhibitorClinical trial
A Phase II, Open-label, Multi-center, Basket Study of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy to Patients With Biologically Selected Advanced or Metastatic Solid Tumors (ARTIST)Status: Recruiting, Estimated PCD: 2025-03-01
Product
MRX-2843Product
BI 1701963Clinical trial
A Phase I, Open Label, Dose Escalation Study of ACE1702 Cell Immunotherapy in Subjects With Advanced or Metastatic HER2-expressing Solid TumorsStatus: Recruiting, Estimated PCD: 2024-06-01
Product
CyclophosphamideClinical trial
A Phase 1/1b Trial of MRTX849 in Combination With BI 1701963 in Patients With Advanced Solid Tumors With KRAS G12C MutationStatus: Completed, Estimated PCD: 2022-11-02
Product
ACE1702Product
FludarabineProduct
NG-641 + NivolumabClinical trial
A Multicentre, Open-label, Non-randomised First in Human Study of NG-641, a Tumour Selective Transgene Expressing Adenoviral Vector, in Patients With Metastatic or Advanced Epithelial Tumours (STAR)Status: Recruiting, Estimated PCD: 2023-12-31
Clinical trial
A Multicentre, Open-label, Non-randomized, Phase 1a/1b Study of NG-641, a Tumour-selective and Transgene-expressing Adenoviral Vector, in Combination With Nivolumab (or Standard of Care PD-1 Inhibition) in Patients With Metastatic or Advanced Epithelial Tumours (NEBULA)Status: Recruiting, Estimated PCD: 2024-05-30
Product
NG-641Clinical trial
Phase 2, Single-Arm, Open-Label, Multi-Center Trial of Second-Line Panitumumab Monotherapy in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and NeckStatus: Completed, Estimated PCD: 2010-12-15
Product
PanitumumabProduct
OR2805Product
DocetaxelClinical trial
A Phase 1-2 Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents in Subjects With Advanced MalignanciesStatus: Recruiting, Estimated PCD: 2024-04-15
Clinical trial
An Open-Label Study of AMG 386 in Combination With Either Paclitaxel and Trastuzumab or Capecitabine and Lapatinib in Subjects With HER2-positive Locally Recurrent or Metastatic Breast CancerStatus: Completed, Estimated PCD: 2014-02-27
Product
AMG 386Product
INV-1120Clinical trial
A Phase 1 Study of TJ033721 in Subjects With Advanced or Metastatic Solid TumorsStatus: Recruiting, Estimated PCD: 2024-09-01
Clinical trial
A Phase 1, Open-Label, Multicenter Trial Investigating the Safety, Tolerability, and Preliminary Antineoplastic Activity of Sym021 (Anti-PD-1) as Monotherapy, in Combination With Either Sym022 (Anti-LAG-3) or Sym023 (Anti-TIM-3), and in Combination With Both Sym022 and Sym023 in Patients With Advanced Solid Tumor Malignancies or LymphomasStatus: Completed, Estimated PCD: 2022-03-23
Product
Sym022Product
Sym021Product
Sym023Clinical trial
A Phase 1a/1b, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Evidence of Antitumor Activity of INV-1120 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced Solid TumorsStatus: Recruiting, Estimated PCD: 2023-07-31
Product
TJ033721Product
AK112Clinical trial
A Multicentre, Open-label, Non-randomized, Phase 1a/1b Study of NG-350A, a Tumour-selective Anti-CD40-expressing Adenoviral Vector, in Combination With Pembrolizumab in Patients With Metastatic or Advanced Epithelial TumoursStatus: Recruiting, Estimated PCD: 2025-03-17
Clinical trial
Phase II Study of AK112 (Anti-PD-1 and VEGF Bi-specific Antibody) in the Treatment of Advanced Gynecological CarcinomaStatus: Active (not recruiting), Estimated PCD: 2023-05-01
Clinical trial
A Phase I Clinical Study to Assess the Safety and Efficacy of CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid TumorsStatus: Recruiting, Estimated PCD: 2025-12-31
Product
NG-350AClinical trial
A Phase 1 Study of HMBD-002-V4C26 (HMBD-002), a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab, in Patients With Advanced Solid MalignanciesStatus: Recruiting, Estimated PCD: 2024-10-01
Product
HMBD-002Clinical trial
A Phase 1b/2a Two-Part, Open-Label, Multicenter Study to Evaluate the Safety and Pharmacokinetics of OC-001 as Monotherapy and in Combination With an Anti-PD-1/Anti-PD-L1 Antibody in Patients With Selected Locally Advanced or Metastatic CancersStatus: Recruiting, Estimated PCD: 2026-03-31
Product
OC-001Clinical trial
A Phase 1 Study of the Combination of Cabozantinib With Trifluridine/Tipiracil (TAS-102) in Patients With Metastatic Colorectal Adenocarcinoma (mCRC)Status: Active (not recruiting), Estimated PCD: 2023-08-29
Product
CabozantinibDrug
TAS-102Product
Anti-CD19 CAR PBLClinical trial
VERIFY: Vedolizumab for the Prevention of Immune Checkpoint Inhibitor Related Diarrhea or Colitis in Patients With Cancer: A Randomized, Double-Blinded, Placebo Controlled TrialStatus: Not yet recruiting, Estimated PCD: 2026-11-01
Product
VedolizumabProduct
PlaceboClinical trial
AcSé CRIZOTINIB : Secured Access to Crizotinib for Patients With Tumors Harboring a Genomic Alteration on One of the Biological Targets of the Drug.Status: Completed, Estimated PCD: 2019-06-01
Product
CrizotinibClinical trial
Pilot Study: Detection of Carcinomas Using 64Cu-Labeled M5A Antibody to Carcinoembryonic Antigen (CEA)Status: Active (not recruiting), Estimated PCD: 2022-03-06
Clinical trial
Phase II Basket Trial to Evaluate Safety and Efficacy of Neratinib, An Irreversible Tyrosine Kinases Inhibitor of EGFR, ERBB2 and ERBB4 Receptors and Trastuzumab Biosimilar (Herzuma®) in Patients With HER2 Mutated Advanced Solid CancersStatus: Active (not recruiting), Estimated PCD: 2023-11-30
Product
NeratinibClinical trial
Phase II Study of Pembrolizumab in Combination With Binimetinib and Bevacizumab in Patients With Refractory Colorectal CancerStatus: Active (not recruiting), Estimated PCD: 2022-04-14
Drug
AtezolizumabProduct
BinimetinibClinical trial
DOSAGE Study: A Multicenter Randomized Phase III Trial of DOSe-reduced Chemotherapy for Advanced Colorectal Cancer in Older PatientsStatus: Not yet recruiting, Estimated PCD: 2028-06-01
Product
Doublet ChemotherapyClinical trial
IMPACT: Immunotherapy in Patients With Metastatic Cancers and CDK12 MutationsStatus: Active (not recruiting), Estimated PCD: 2022-12-22
Clinical trial
An Open-Label Pilot Study to Evaluate Efficacy and Safety of Bevacizumab Via Transarterial Chemoembolization (TACE) in Patients With Liver MetastasesStatus: Not yet recruiting, Estimated PCD: 2024-06-01
Product
MonotherapyClinical trial
A Phase 2 Basket Trial of an ERK1/2 Inhibitor (LY3214996) in Combination With Abemaciclib for Patients Whose Tumors Harbor Pathogenic Alterations in BRAF, RAF1, MEK1/2, ERK1/2, and NF1.Status: Terminated, Estimated PCD: 2023-08-07
Product
AbemaciclibProduct
LY3214996Clinical trial
An Open-Label Randomized Phase II Study of Combining Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor (TKI)-naïve Epidermal Growth Factor Receptor (EGFR)-Mutant Locally Advanced or Metastatic NSCLCStatus: Active (not recruiting), Estimated PCD: 2024-05-01
Drug
OsimertinibProduct
RamucirumabClinical trial
An Adaptive First-in-human Trial of PhOx430, a First-in-class Acetylglucosaminyltransferase V Inhibitor, in Patients With Advanced Solid Tumours (PhAST Trial)Status: Recruiting, Estimated PCD: 2024-07-08
Product
PhOx430Clinical trial
A Phase II Trial of T Cell Receptor Gene Therapy Targeting Human Papillomavirus ( HPV) 16 E7 for HPV-Associated CancersStatus: Recruiting, Estimated PCD: 2025-01-01
Product
E7 TCR-T cellsClinical trial
Pilot Study of Non-invasive Measurement of PD-L1 Levels With Positron Emission Tomography (PET) in Head and Neck Malignancies and Intracranial MetastasesStatus: Terminated, Estimated PCD: 2024-01-31
Product
Adnectin 18F-BMS-986192Clinical trial
A Phase 1, Open-Label, Multicenter Trial Investigating the Safety, Tolerability, and Preliminary Antineoplastic Activity of Sym024 (Anti-CD73) as Monotherapy and in Combination With Sym021 (Anti-PD-1) in Patients With Advanced Solid Tumor MalignanciesStatus: Active (not recruiting), Estimated PCD: 2024-12-01
Product
Sym024Clinical trial
Phase 1 Trial of SYNC-T - Immunotherapy Regimen Given After Controlled Cellular Lysis for Patients With Advanced/Metastatic Solid TumorsStatus: Recruiting, Estimated PCD: 2024-12-31
Product
SV-101Clinical trial
Phase I Study of the PKMYT1 Inhibitor RP-6306 in Combination With Carboplatin and Paclitaxel for the Treatment of Recurrent TP53 Ovarian and Uterine CancerStatus: Active (not recruiting), Estimated PCD: 2026-12-04
Product
RP-6306Product
CarboplatinClinical trial
A Phase I Study Assessing the Safety and Tolerability of Ascending Doses of AZD1390 in Combination With Stereotactic Body Radiation Therapy (SBRT) in Patients With Metastatic Solid Tumor MalignanciesStatus: Recruiting, Estimated PCD: 2028-05-17
Drug
AZD1390Clinical trial
Open-label First Line, Single-arm Phase II Study of CisGem Combined With Pembrolizumab in Patients With Advanced or Metastatic Biliary Tract CancerStatus: Completed, Estimated PCD: 2023-04-27
Drug
CisplatinDrug
GemcitabineClinical trial
Phase 2 Study of 9-ING-41, a Glycogen Synthase Kinase 3 Beta (GSK 3β) Inhibitor, Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland CarcinomaStatus: Active (not recruiting), Estimated PCD: 2024-06-01
Product
9-ING-41Clinical trial
An Open-label, Phase II Study of Durvalumab (MEDI4736) in Combination With Cetuximab in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)Status: Active (not recruiting), Estimated PCD: 2024-12-01
Product
DurvalumabClinical trial
A Phase 2, Multi-centre, Open-label Study of Avelumab (MSB0010718C) in Locally Advanced or Metastatic Penile Cancer Patients Unfit for Platinum-based Chemotherapy or Progressed On or After Platinum-based ChemotherapyStatus: Recruiting, Estimated PCD: 2024-06-30
Clinical trial
Open-label, Randomized, Multicenter, Phase III Study, Comparing Standard Chemotherapy to Standard Combination of Endocrine Therapy With Abemaciclib as Initial Metastatic Treatment Among Patients With Visceral Metastasis of ER+ HER2-breast Cancer, High Burden DiseaseStatus: Recruiting, Estimated PCD: 2024-12-01
Product
CapecitabineProduct
LetrozoleProduct
AnastrozoleProduct
FulvestrantClinical trial
A Phase II Trial of Hypofractionated Radiotherapy in Patients With Limited Progression on Immune Checkpoint BlockadeStatus: Recruiting, Estimated PCD: 2025-10-01
Clinical trial
A Phase II Trial of OnapriStone in CoMbInation With FuLvestrant for Patients With ER-positive, and HER2-negative Metastatic Breast Cancer After Progression on Endocrine Therapy and CDK 4/6 InhibitorsStatus: Terminated, Estimated PCD: 2023-04-03
Product
OnapristoneClinical trial
A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial CarcinomaStatus: Recruiting, Estimated PCD: 2024-12-11
Product
FutibatinibClinical trial
A Novel Molecularly Targeted Theranostic Approach Via the αvβ6 Integrin for the Detection and Treatment of Metastatic CarcinomasStatus: Recruiting, Estimated PCD: 2027-03-31
Clinical trial
Phase II Trial of pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate CancerStatus: Active (not recruiting), Estimated PCD: 2025-01-01
Product
pTVG-HPClinical trial
Phase II Study of Intrathecal I-3F8 in Patients With GD2-Expressing Central Nervous System and Leptomeningeal NeoplasmsStatus: Completed, Estimated PCD: 2023-02-01
Clinical trial
Improving Public Cancer Care by Implementing Precision Medicine in Norway A Multi-cohort Phase 2 Treatment Clinical Study Investigating Efficacy of Approved Drugs Outside Indication in Patients With Advanced CancerStatus: Recruiting, Estimated PCD: 2040-03-30
Clinical trial
Immunotherapy Using Precision T Cells Specific to Personalized Neo-antigen for the Treatment of Advanced Solid TumorStatus: Recruiting, Estimated PCD: 2024-12-31
Product
TILDrug
interleukin-2Drug
cyclophosphamideDrug
fludarabineClinical trial
A Phase I/II Dose Escalation, Safety and Efficacy Study of Anti-NY-ESO-1 T Cell Receptor (TCR)-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic CancersStatus: Recruiting, Estimated PCD: 2027-12-30
Product
HBI 0201-ESO TCRTClinical trial
PROstate-specific Membrane Antigen DosImetry-Guided endoradiotherapY: A Phase 1/2 Study of Personalized PSMA Radiopharmaceutical Therapy (PRODIGY-1)Status: Not yet recruiting, Estimated PCD: 2028-06-15
Product
177Lu-PSMA-I&TClinical trial
Window of Opportunity Assessment of [Fam-]Trastuzumab DERuxtecan-nxki (T-DXd) Brain Tumor Penetration and Efficacy (WOnDER-BT)Status: Recruiting, Estimated PCD: 2027-09-22
Product
Trastuzumab deruxtecanClinical trial
Integrating Minimally Invasive Biomarkers of Estrogen Signaling to Detect Endocrine Therapy Resistance in Metastatic Invasive Lobular Breast CancerStatus: Recruiting, Estimated PCD: 2026-01-01
Clinical trial
A Multicenter, Randomised, Comparative, Open-label Phase III Aiming to Compare the Survival of Patients With Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas Treated by a Combination of Immune Checkpoint Inhibitors (Botensilimab + Balstilimab) Versus the Standard of Care (FOLFOX/XELOX + Nivolumab)Status: Not yet recruiting, Estimated PCD: 2028-05-15
Product
BalstilimabDrug
BotensilimabProduct
FolfoxDrug
XELOXDrug
T-VECClinical trial
RP-3500 (ATRi) + External Beam Radiotherapy (EBRT) for the Palliative Treatment of Metastatic DiseaseStatus: Recruiting, Estimated PCD: 2025-09-30
Product
RP-3500Clinical trial
A Phase II Study of Intraperitoneal (IP) Plus Intravenous (IV) Chemotherapy Versus IV Carboplatin Plus Paclitaxel in Patients With Epithelial Ovarian Cancer Optimally Debulked at Surgery Following Neoadjuvant Intravenous ChemotherapyStatus: Completed, Estimated PCD: 2016-03-10
Drug
carboplatinProduct
cisplatinDrug
paclitaxelClinical trial
A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid TumorsStatus: Recruiting, Estimated PCD: 2025-03-01
Product
IPH5301Clinical trial
A Master Rollover Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s)Status: Recruiting, Estimated PCD: 2026-08-03
Clinical trial
Phase I/II Trial Investigating the Safety, Tolerability, Pharmacokinetics, Immune and Clinical Activity of SX-682 in Combination With BinTrafusp Alfa (M7824 or TGF-beta "Trap"/PD-L1) With CV301 TRICOM in Advanced Solid Tumors (STAT)Status: Completed, Estimated PCD: 2023-02-07
Drug
SX-682Product
M7824Product
MVA-BN-CV301Product
pTVG-ARDrug
mFOLFOX6Clinical trial
A Phase II Study of the Rate of Conversion to Complete Resection in Patients With Initially Inoperable Hepatic-Only Metastases From Colorectal Cancer After Treatment With Hepatic Arterial Infusion With Floxuridine and Dexamethasone in Combination With Best Systemic ChemotherapyStatus: Active (not recruiting), Estimated PCD: 2025-05-01
Drug
dexamethasoneProduct
floxuridineDrug
fluorouracilDrug
leucovorinDrug
mFOLFIRINOXClinical trial
Phase II Multicenter Clinical Trial on Imatinib Treatment for Patients With Resectable Hepatic Metastasis From Gastrointestinal Stromal Tumors (GISTs)Status: Completed, Estimated PCD: 2016-03-01
Product
ImatinibClinical trial
PRE-Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis: A Phase I/Ib Platform TrialStatus: Recruiting, Estimated PCD: 2026-12-30
Product
ALX148Product
Fam-Trastuzumab DeruxtecanProduct
ZanidatamabDrug
TucatinibClinical trial
Effect of Dexmedetomidine Infusion, Lidocaine Infusion, and Intrathecal Morphine Injection on Biomarker for Perioperative Stress and Immune Response, and Cancer Progression and Metastasis in Colorectal Cancer SurgeryStatus: Completed, Estimated PCD: 2023-07-05
Product
LidocaineProduct
DexmedetomidineProduct
Intrathecal morphineClinical trial
Early Nutrition Intervention for M1 Stage Cancer Patients：a Single-center,Open,Randomized Controlled TrialStatus: Recruiting, Estimated PCD: 2025-01-01
Product
Early Nutrition InterventionClinical trial
An Exploratory Clinical Study to Evaluate the Efficacy and Safety of Penpulimab in Combination With Cetuximab as First-line Treatment in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (R/MSCCHN)Status: Recruiting, Estimated PCD: 2024-12-25
Product
Penpulimab + CetuximabClinical trial
A Phase I Study of Actinium-225 Labeled Humanized Anti-CEA M5A Antibody in Patients With CEA Producing Advanced or Metastatic CancersStatus: Recruiting, Estimated PCD: 2025-08-07
Clinical trial
Personalized Vaccine Generated by Autologous Dendritic Cells Pulsed With Autologous Whole Tumor Cell Lysate Treat Advanced Solid Tumor Patients With High Tumor Mutation BurdenStatus: Withdrawn, Estimated PCD: 2021-12-30
Product
Personalized DC VaccineClinical trial
Low-dose 500 mg Abiraterone Acetate in Metastatic Castration-resistant Prostate Cancer (mCRPC) and Metastatic Hormone-sensitive Prostate Cancer (mHSPC) Patients: a Phase I Proof-of-concept Clinical StudyStatus: Active (not recruiting), Estimated PCD: 2023-09-05
Product
FAP-2286Clinical trial
Randomized, Double-Blind, Phase 2 Study of Ramucirumab or Merestinib or Placebo Plus Cisplatin and Gemcitabine as First-Line Treatment in Patients With Advanced or Metastatic Biliary Tract CancerStatus: Active (not recruiting), Estimated PCD: 2018-02-16
Product
MerestinibClinical trial
A Single-center, Phase 1 Dose Escalation Study of Trametinib Combined With HDM201 in Patients With RAS/RAF Mutant and TP53 Wild-type Advanced/Metastatic Colorectal Cancer.Status: Completed, Estimated PCD: 2023-09-12
Product
HDM201Product
TrametinibClinical trial
Phase II Prospective Study of Bintrafusp Alfa in Previously Treated Patients With Recurrent and Metastatic (R/M) Non-keratinizing Nasopharyngeal Carcinoma (NPC)Status: Completed, Estimated PCD: 2022-09-30
Product
Bintrafusp AlfaClinical trial
A PROSPECTIVE RANDOMIZED TRIAL OF BLEOMYCIN VS. DOXYCYCLINE VS. TALC FOR THE INTRAPLEURAL TREATMENT OF MALIGNANT PLEURAL EFFUSIONSStatus: , Estimated PCD: 2003-02-01
Product
BleomycinProduct
doxycyclineClinical trial
A Phase 2 Study to Evaluate the Triplet Combination of Pemetrexed Plus AB928 (Etrumadenant) + AB122 (Zimberelimab) in Patients With Previously Treated Advanced or Metastatic MTAP Deficient Urothelial CarcinomaStatus: Recruiting, Estimated PCD: 2025-09-30
Product
PemetrexedProduct
ZimberelimabDrug
EtrumadenantClinical trial
Patients Characteristics, Treatment Pattern & Outcomes of Patients With Advanced, Recurrent or Metastatic Endometrial Carcinoma: A Retrospective StudyStatus: Completed, Estimated PCD: 2022-11-22
Drug
DocetaxelClinical trial
KOrean Precision Medicine Networking Group Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors IIStatus: Recruiting, Estimated PCD: 2025-09-01
Drug
ErlotinibProduct
Trastuzumab + PertuzumabProduct
Trastuzumab emtansineProduct
VemurafenibProduct
Bevacizumab + ErlotinibDrug
EntrectinibDrug
PralsetinibClinical trial
A Phase II Study of Temozolomide and Radiation Therapy in Patients With Brain Metastasis From Non-small Cell Lung Cancer (NSCLC)Status: Completed, Estimated PCD: 2008-08-01
Product
TMZClinical trial
Phase II Trial of Lurbinectedin Combined With Avelumab as Switch Maintenance Firstline Therapy for Metastatic Urothelial Carcinoma With Stable or Responding Disease Following Platinum-based ChemotherapyStatus: Recruiting, Estimated PCD: 2026-11-01
Product
Avelumab + LurbinectedinClinical trial
Randomized Phase II Study of Checkpoint Blockade Immunotherapy Combined With Stereotactic Body Radiation Therapy in Advanced Metastatic DiseaseStatus: Active (not recruiting), Estimated PCD: 2021-08-16
Clinical trial
Phase 1, FIH, Open-label, Nonrandomized, Multicenter Study of JZP815 in Participants With Advanced or Metastatic Solid Tumors Harboring Alterations in the MAPK PathwayStatus: Recruiting, Estimated PCD: 2028-04-01
Product
JZP815Clinical trial
Feasibility of a Digital Medicine Program in Optimizing Opioid Pain Control in Cancer PatientsStatus: Terminated, Estimated PCD: 2020-09-16
Product
Oxycodone + AcetaminophenClinical trial
Implementing Precision Medicine in cOmmunity HospiTALsStatus: Recruiting, Estimated PCD: 2024-04-15
Product
Biopsy LiquidClinical trial
A Prospective Study of Hyperthermia Combined With Autologous Adoptive Cellular Immunotherapy in the Treatment of Abdominal and Pelvic Malignancies or MetastasesStatus: Completed, Estimated PCD: 2022-12-31
Drug
AN0025Clinical trial
A Phase I Study Of Hepatic Arterial Infusion With Floxuridine And Dexamethasone In Combination With Intravenous Oxaliplatin Plus 5-Fluorouracil And Leucovorin As Adjuvant Treatment After Resection Of Hepatic Metastases From Colorectal CancerStatus: Active (not recruiting), Estimated PCD: 2024-06-01
Product
FOLFOXDrug
oxaliplatinClinical trial
The IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors: A Phase 1b Study to Evaluate the Safety, Determine Recommended Phase 2 Dose (RP2D), and Investigate the Biologic and Clinical ActivityStatus: Completed, Estimated PCD: 2021-02-21
Product
IRX 2Clinical trial
A Phase Ib/II Open Label, Multi-arm, Parallel Cohort Dose Finding and Expansion Study to Assess the Safety, Pharmacokinetics and Efficacy of NUC-3373, a Nucleotide Analogue, Given in Combination With Standard Approved Agents in Patients With Advanced Solid TumoursStatus: Recruiting, Estimated PCD: 2024-08-01
Product
FosifloxuridineClinical trial
A Randomized Study Investigating the Pharmacokinetics of Standard Interval Dosing Compared to Extended Interval Dosing of Nivolumab or Pembrolizumab in Locally Advanced or Metastatic CancersStatus: Recruiting, Estimated PCD: 2025-04-12
Clinical trial
TEMPLE - Thiopurine Enhanced Mutations for PD-1/Ligand-1 EfficacyStatus: Recruiting, Estimated PCD: 2024-08-31
Product
AtezolizumabClinical trial
A Phase II Clinical Trial of Bevacizumab Plus eRlotinIb in patientS With Advanced Cancer Having Genetic Alterations in Krebs Cycle (BRISK, KCSG AL22-16)Status: Recruiting, Estimated PCD: 2025-01-31
Drug
bevacizumabProduct
erlotinibClinical trial
A Phase I Study of GNX102 in Patients With Advanced Solid TumorsStatus: Terminated, Estimated PCD: 2023-07-26
Product
GNX102Clinical trial
18F-Clofarabine (CFA) as a PET Imaging Agent to Measure Deoxycytidine Kinase (DCK) Activity in Metastatic Cancer, as a Candidate Predictive Biomarker for Response to DCK-dependent Drugs Such as GemcitabineStatus: Recruiting, Estimated PCD: 2024-06-05
Product
18F-ClofarabineClinical trial
A Phase II Study of Denosumab in Combination With Enzalutamide in Progressive Metastatic Castrate-resistant Prostate Cancer and Bone Metastases.Status: Terminated, Estimated PCD: 2019-01-12
Product
XgevaDrug
enzalutamideClinical trial
PEACE V: A Randomized Phase II Trial for the Salvage Treatment of OligoRecurrent Nodal Prostate Cancer Metastases (STORM)Status: Active (not recruiting), Estimated PCD: 2023-04-30
Clinical trial
Evaluation of Efficacy of Comprehensive Genomic Tumour Profiling (CGP) From Liquid and/or Tissue Biopsy in Patients With Locally Advanced and/or Metastatic CarcinomaStatus: Recruiting, Estimated PCD: 2024-04-01
Product
Biomarker MonitoringClinical trial
The Value of Molecular Residual Disease Monitoring Based on ctDNA in Advanced or Metastatic Pancreatic CancerStatus: Recruiting, Estimated PCD: 2025-02-01
Product
Later-line therapyClinical trial
Chemoembolization in Hepatocellular Carcinoma or Neuroendocrine Hepatic Metastases: A Phase II Multi-Center TrialStatus: Completed, Estimated PCD: 2011-05-01
Drug
doxorubicinProduct
mitomycinClinical trial
Prediction of Immune-related Adverse Events Induced by Anti-CTLA4 and Anti-PD1/PDL1 Drugs by Means of a Battery of Autoantibodies. A Multicenter Prospective Observational Cohort StudyStatus: Recruiting, Estimated PCD: 2023-10-31
Product
Immune checkpoint inhibitorsClinical trial
Arginase-1 Peptide Vaccine in Patients With Metastatic Solid TumorsStatus: Completed, Estimated PCD: 2022-01-19
Product
ARG1-18,19,20Clinical trial
RNASARC - Molecular Screening Program of Soft Tissue Sarcomas With Complex Genomic Profile to Detect NTRK1/2/3, ROS1 or ALK Gene Fusions.Status: Active (not recruiting), Estimated PCD: 2024-02-15
Product
Blood and tumor samplesClinical trial
A Phase II Trial Aiming to Evaluate the Clinical Interest of ABEMACICLIB Monotherapy in Patients With Locally Advanced/Metastatic Head and Neck Cancer After Failure of Platinum and Cetuximab or Anti-EGFR-based Therapy and Harboring an Homozygous Deletion of CDKN2A, and/or an Amplification of CCND1 and/or of CDK6Status: Completed, Estimated PCD: 2022-11-05
Clinical trial
A Randomized Non-comparative Phase II Study of Maintenance Therapy With OSE2101 Plus FOLFIRI, or FOLFIRI After Induction Therapy With FOLFIRINOX in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (TEDOPaM-D17-01 PRODIGE 63 Study)Status: Recruiting, Estimated PCD: 2023-12-30
Product
FOLFIRIProduct
OSE2101Clinical trial
Investigation of the Timely-coordinated Therapy of Patients With Metastatic Cancer by Radiotherapy Together With Immune Checkpoint InhibitionStatus: Completed, Estimated PCD: 2021-02-28
Drug
LurbinectedinClinical trial
Triage of Advanced Cervical Cancer Through Immunotherapy Induction (TRACTION)Status: Recruiting, Estimated PCD: 2026-06-30
Product
MGD019Clinical trial
ISPY-P1.01: Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer: A Phase I/Ib TrialStatus: Withdrawn, Estimated PCD: 2021-11-17
Product
Vic-trastuzumab duocarmazineClinical trial
A Phase 2 Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate CancerStatus: Recruiting, Estimated PCD: 2024-05-12
Clinical trial
Stereotactic Body Radiotherapy With or Without Darolutamide for OligoRecurrent Prostate Cancer: a Randomized Phase II Trial (DART)Status: Recruiting, Estimated PCD: 2026-02-12
Product
DarolutamideClinical trial
A Phase 1 Feasibility Study of Cholesterol Metabolism Reprogramming (Evolocumab, Atorvastatin and Ezetimibe) in Combination With the Standard of Care in Patients With Advanced or Metastatic Pancreatic AdenocarcinomaStatus: Active (not recruiting), Estimated PCD: 2025-01-31
Drug
TrastuzumabClinical trial
a New Spark in Treating Oligorecurrent Prostate Cancer: Adding Systemic Treatment to Stereotactic Body Radiotherapy or Metastasectomy: Key to Long-lasting Event-free Survival?Status: Recruiting, Estimated PCD: 2027-04-25
Drug
goserelinClinical trial
Implementing Precision Medicine in cOmmunity HospiTALsStatus: Recruiting, Estimated PCD: 2024-11-15
Product
Biopsy